Finding 50% effective dose of remimazolam for facilitating I-gel insertion with remifentanil target-controlled infusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007801

Enrollment

Registered

2022-10-12

Start date

2022-10-05

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Remimazolam, the dose starting on 0.05 mg/kg, once, during induction, IV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients aged 19-65 years with ASA score 1 or 2 scheduled for general anesthesia and eligible for I-gel use

Exclusion criteria

Exclusion criteria: BMI > 30 kg/m2 Patient refusal Anticipated difficult airway Anticipated difficult mask ventilation COPD, astham, pneumonia, active URI Risk of aspiration Patients unable to response on verbal command History of allergies to benzodiazepines History of allergies to opioids History of substance abuse/addiction Pregnant or breastfeeding patients

Design outcomes

Primary

Measure	Time frame
Dose of remimazolam associated with 50% probability for adequate depth of anesthesia for I-gel insertion with remifentanil target controlled infusion	—

Secondary

Measure	Time frame
vital signs (Mean arterial pressure, heartrate, oxygen saturation), Bispectral index(BIS), loss of consciousness time, I-gel insertion time	—

Countries

Korea, Republic of

Contacts

Public ContactJu Yeon Oh

Ajou University Hospital

itisamy@hanmail.net+82-31-219-4916

Outcome results